Hasan Terzi1, Teksin Cırpan2, Rabia Terzi3, Ahmet Özgür Yeniel2, Hüseyin Aktuğ4, Onur Bilgin2. 1. Department of Gynecology and Obstetrics, Derince Training and Research Hospital, Kocaeli, Turkey. 2. Department of Gynecology and Obstetrics, Faculty of Medicine, Ege University, İzmir, Turkey. 3. Department of Physical Medicine and Rehabilitation, Derince Training and Research Hospital, Kocaeli, Turkey. 4. Department of Histology, Faculty of Medicine, Ege University, İzmir, Turkey.
Abstract
OBJECTIVE: We aimed to determine the effect of hormone replacement therapy on bone microarchitecture in ovariectomized rats. MATERIAL AND METHODS: In the Animal Ethics Committee approved-study, the effect of treatment with 17 β-estradiol 50 μg/kg and medroxyprogesterone 2.5 mg/kg on bone architecture and bone mineral density in rats versus ovariectomized control rats over the course of 20 days were evaluated. Femoral and lumbar bone mineral density levels and morphometric measurements were performed. RESULTS: There were no significant differences in the femoral and lumbar bone mineral density levels between the groups. In the intact control group, the trabecular structures were significantly superior to those in the other groups. Additionally, the osteoblast count was significantly higher while the osteoclast count was significantly lower than in all other groups. Two parameters reflecting trabecular bone microarchitecture, which include the trabecular count and the trabecular area, demonstrated significant improvement in the hormone replacement group when compared to the ovariectomized control group. In the hormone replacement groups, the osteoblast count was significantly higher while the osteoclast count was significantly lower than in the ovariectomized control group. CONCLUSION: We suggest that offering estrogen alone or in combination with progestogen can be a beneficial approach in preventing early postmenopausal bone loss regardless of bone mineral density.
OBJECTIVE: We aimed to determine the effect of hormone replacement therapy on bone microarchitecture in ovariectomized rats. MATERIAL AND METHODS: In the Animal Ethics Committee approved-study, the effect of treatment with 17 β-estradiol 50 μg/kg and medroxyprogesterone 2.5 mg/kg on bone architecture and bone mineral density in rats versus ovariectomized control rats over the course of 20 days were evaluated. Femoral and lumbar bone mineral density levels and morphometric measurements were performed. RESULTS: There were no significant differences in the femoral and lumbar bone mineral density levels between the groups. In the intact control group, the trabecular structures were significantly superior to those in the other groups. Additionally, the osteoblast count was significantly higher while the osteoclast count was significantly lower than in all other groups. Two parameters reflecting trabecular bone microarchitecture, which include the trabecular count and the trabecular area, demonstrated significant improvement in the hormone replacement group when compared to the ovariectomized control group. In the hormone replacement groups, the osteoblast count was significantly higher while the osteoclast count was significantly lower than in the ovariectomized control group. CONCLUSION: We suggest that offering estrogen alone or in combination with progestogen can be a beneficial approach in preventing early postmenopausal bone loss regardless of bone mineral density.
Entities:
Keywords:
Hormone replacement therapy; bone density; bone microarchitecture; menopause; ovariectomy
Authors: A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker Journal: J Bone Miner Res Date: 1987-12 Impact factor: 6.741
Authors: Richard J Santen; D Craig Allred; Stacy P Ardoin; David F Archer; Norman Boyd; Glenn D Braunstein; Henry G Burger; Graham A Colditz; Susan R Davis; Marco Gambacciani; Barbara A Gower; Victor W Henderson; Wael N Jarjour; Richard H Karas; Michael Kleerekoper; Roger A Lobo; JoAnn E Manson; Jo Marsden; Kathryn A Martin; Lisa Martin; JoAnn V Pinkerton; David R Rubinow; Helena Teede; Diane M Thiboutot; Wulf H Utian Journal: J Clin Endocrinol Metab Date: 2010-06-21 Impact factor: 5.958
Authors: Jane A Cauley; John Robbins; Zhao Chen; Steven R Cummings; Rebecca D Jackson; Andrea Z LaCroix; Meryl LeBoff; Cora E Lewis; Joan McGowan; Joan Neuner; Mary Pettinger; Marcia L Stefanick; Jean Wactawski-Wende; Nelson B Watts Journal: JAMA Date: 2003-10-01 Impact factor: 56.272
Authors: George Wells; Peter Tugwell; Beverley Shea; Gordon Guyatt; Joan Peterson; Nicole Zytaruk; Vivian Robinson; David Henry; Diane O'Connell; Ann Cranney Journal: Endocr Rev Date: 2002-08 Impact factor: 19.871
Authors: Glenn A Ladinsky; Branimir Vasilic; Andra M Popescu; Michael Wald; Babette S Zemel; Peter J Snyder; Louise Loh; Hee Kwon Song; Punam K Saha; Alexander C Wright; Felix W Wehrli Journal: J Bone Miner Res Date: 2008-01 Impact factor: 6.741